MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction

• Register: ClinicalTrials.gov
• Last refreshed on: 11 April 2016
• Main ID: NCT00859300
• Date of registration: 05/03/2008
• Prospective Registration: No
• Primary sponsor: Hospices Civils de Lyon
• Public title: MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction MAP-IDM
• Scientific title: MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction. A Case Control Study
• Date of first enrolment: December 2007
• Target sample size: 1011
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00859300
• Study type: Observational
• Study design: Observational Model: Case Control, Time Perspective: Prospective
• Phase: N/A

Countries of recruitment

France

Contacts

• Name: CHEVALIER Philippe, MD
• Affiliation: Hospices Civils de Lyon

Key inclusion & exclusion criteria

Inclusion Criteria:

- All patients admitted to ICU for MI and presenting the following criteria:

- Age > 18

- Group 1 (Case) Patients with cardiac arrest and ventricular fibrillation developed up
to 24 h post MI Group 2 (control) Patients with MI (no ventricular fibrillation)

- Written informed consent.

Exclusion Criteria:

- No written informed consent

- Known Medical History of cardiomyopathy, including acute coronary syndrome



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Myocardial Infarction

Intervention(s)

Genetic: Blood sample

Primary Outcome(s)

Correlation phenotype/genotype of sudden death at the acute phase of myocardial infarct. [Time Frame: Correlation phenotype/genotype]

Secondary ID(s)

2007.463

Source(s) of Monetary Support

Please refer to primary and secondary sponsors